Hepatitis B virus and HIV coinfection: Relationship of different serological patterns to survival and liver disease

HIV Medicine

Volumn 8, Issue 5, 2007, Pages 271-279

  Osborn, Melissa K ^a   Guest, J L ^b,c   Rimland, D ^a,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

Hepatitis B virus; HIV; Liver disease; Mortality

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; CD4 ANTIGEN; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; COMORBIDITY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HAZARD RATIO; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEROLOGY; STATISTICAL SIGNIFICANCE; SUPERINFECTION; SURVIVAL RATE; TREND STUDY;

ADOLESCENT; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASPARTATE AMINOTRANSFERASES; COHORT STUDIES; FEMALE; GEORGIA; HEPATITIS B CORE ANTIGENS; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV; HIV INFECTIONS; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 34250160862     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2007.00469.x     Document Type: Article

References (43)

1. Mocroft A, Vella S, Benfield TL et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352: 1725-1730.
2. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.
3. Bica I, McGovern B, Dhar R et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492-497.
4. Louie JK, Hsu LC, Osmond DH, Katz MH, Schwarcz SK. Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-98. J Infect Dis 2002; 186: 1023-1027.
5. Martin-Carbonero L, Soriano V, Valencia E, Garcia-Samaniego J, Lopez M, Gonzalez-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 2001; 17: 1467-1471.
6. Thio CL, Seaberg EC, Skolasky R Jr et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921-1926.
7. Page-Shafer K, Delorenze GN, Satariano WA, Winkelstein W Jr. Comorbidity and survival in HIV-infected men in the San Francisco Men's Health Survey. Ann Epidemiol 1996; 6: 420-430.
8. Sinicco A, Raiteri R, Sciandra M et al. Coinfection and superinfection of hepatitis B virus in patients infected with human immunodeficiency virus: No evidence of faster progression to AIDS. Scand J Infect Dis 1997; 29: 111-115.
9. Ockenga J, Tillmann HL, Trautwein C, Stoll M, Manns MP, Schmidt RE. Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J Hepatol 1997; 27: 18-24.
10. Gilson RJ, Hawkins AE, Beecham MR et al. Interactions between HIV and hepatitis B virus in homosexual men: Effects on the natural history of infection. AIDS 1997; 11: 597-606.
11. Scharschmidt BF, Held MJ, Hollander HH et al. Hepatitis B in patients with HIV infection: Relationship to AIDS and patient survival. Ann Intern Med 1992; 117: 837-838.
12. Diamondstone LS, Blakley SA, Rice JC, Clark RA, Goedert JJ. Prognostic factors for all-cause mortality among hemophiliacs infected with human immunodeficiency virus. Am J Epidemiol 1995; 142: 304-313.
13. Dimitrakopoulos A, Takou A, Haida A, Molangeli S, Gialeraki A, Kordossis T. The prevalence of hepatitis B and C in HIV-positive Greek patients: relationship to survival of deceased AIDS patients. J Infect 2000; 40: 127-131.
14. Sheng WH, Chen MY, Hsieh SM et al. Impact of chronic hepatitis B virus (HBV) infection on outcomes of patients infected with HIV in an area where HBV infection is hyperendemic. Clin Infect Dis 2004; 38: 1471-1477.
15. Konopnicki D, Mocroft A, deWit S et al. Hepatitis B and HIV: Prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19: 593-601.
16. Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: A cohort study. AIDS 2004; 18: 2039-2045.
17. Francisci D, Baldelli F, Papili R, Stagni G, Pauluzzi S. Prevalence of HBV, HDV and HCV hepatitis markers in HIV-positive patients. Eur J Epidemiol 1995; 11: 123-126.
18. Shire NJ, Rouster SD, Rajicic N, Sherman KE. Occult hepatitis B in HIV-infected patients. J Acquir Immune Defic Syndr 2004; 36: 869-875.
19. Neau D, Winnock M, Galperine T et al. Isolated antibodies against the core antigen of hepatitis B virus in HIV-infected patients. HIV Med 2004; 5: 171-173.
20. Neau D, Winnock M, Jouvencel AC et al. Occult hepatitis B virus infection in HIV-infected patients with isolated antibodies to hepatitis B core antigen: Aquitaine cohort, 2002-03. Clin Infect Dis 2005; 40: 750-753.
21. Piroth L, Binquet C, Vergne M. et al. The evolution of hepatitis B virus serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV infected patients. J Hepatol 2002; 36: 681-686.
22. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41: 1-19.
23. Saillour F, Dabis F, Dupon M et al. Prevalence and determinants of antibodies to hepatitis C virus and markers for hepatitis B virus infection in patients with HIV infection in Aquitaine. Groupe d'Epidemiologie Clinique du SIDA en Aquitaine. Br Med J 1996; 313: 461-464.
24. McQuillan GM, Coleman PJ, Kruszon-Moran D, Moyer LA, Lambert SB, Margolis HS. Prevalence of hepatitis B virus infection in the United States: The National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999; 89: 14-18.
25. Perrillo RP. Acute flares in chronic hepatitis B: The natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120: 1009-1022.
26. Carr A, Cooper DA. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet 1997; 349: 995-996.
27. Drake A, Mijch A, Sasadeusz J. Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART. Clin Infect Dis 2004; 39: 129-132.
28. Manegold C, Hannoun C, Wywiol A et al. Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2001; 32: 144-148.
29. Lincoln D, Petoumenos K, Dore GJ. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med 2003; 4: 241-249.
30. Gandhi RT, Wurcel A, McGovern B et al. Low prevalence of ongoing hepatitis B viremia in HIV-positive individuals with isolated antibody to hepatitis B core antigen. J Acquir Immune Defic Syndr 2003; 34: 439-441.
31. Jilg W, Sieger E, Zachoval R, Schatzl H. Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B infection: High percentage of carriers of hepatitis B and C virus. J Hepatol 1995; 23: 14-20.
32. Gandhi RT, Wurcel A, Lee H et al. Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1-infected individuals. Clin Infect Dis 2003; 36: 1602-1605.
33. Davaro RE, Cheeseman SH, Keroack MA, Ellison RT III. The significance of isolated antibody to hepatitis B core antigen seropositivity in patients infected with human immunodeficiency virus. Clin Infect Dis 1996; 23: 189-190.
34. Noborg U, Gusdal A, Horal P, Lindh M. Levels of viraemia in subjects with serological markers of past or chronic hepatitis B virus infection. Scand J Infect Dis 2000; 32: 249-252.
35. Weber B, Melchior W, Gehrke R, Doerr HW, Berger A, Rabenau H. Hepatitis B virus markers in anti-HBc only positive individuals. J Med Virol 2001; 64: 312-319.
36. Joller-Jemelka HI, Wicki AN, Grob PJ. Detection of HBs antigen in 'anti-HBc alone' positive sera. J Hepatol 1994; 21: 269-272.
37. Nunez M, Rios P, Perez-Olmeda M, Soriano V. Lack of 'occult' hepatitis B virus infection in HIV-infected patients. AIDS 2002; 16: 2099-2101.
38. Hoofnagle JH, Seeff LB, Bales ZB, Zimmerman HJ. Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med 1978; 298: 1379-1383.
39. Dickson RC, Everhart JE, Lake JR et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997; 113: 1668-1674.
40. Uemoto S, Sugiyama K, Marusawa H et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 1998; 65: 494-499.
41. Wachs ME, Amend WJ, Ascher NL et al. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation 1995; 59: 230-234.
42. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341: 22-26.
43. Cooper C, Kilby D. Clinical significance of hepatitis B core antibody positivity in HCV-infected and HCV/HIV coinfected individuals. Clin Infect Dis 2004; 38: 1335-1337.